Wound Healing Pressure Ulcer Venous Ulcer Wound Fluid Diabetic Ulcer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Leigh IM, Purkis PE, Navsaria HA, et al: Treatment of chronic venous ulcers with sheets of cultured allogenic keratinocytes. Br J Dermatol 1987; 117:591–597PubMedGoogle Scholar
  2. 2.
    Phillips TJ, Gilchrest BA: Cultured allogenic keratinocyte grafts in the management of wound healing: prognostic factors. J Dermatol Surg Oncol 1989; 15:1169–1176PubMedGoogle Scholar
  3. 3.
    Stanulis-Praeger BM, Gilchrest BA: Growth factor responsiveness declines during adulthood for human skin-derived cells. Mech Ageing Dev 1986; 35:85–198CrossRefGoogle Scholar
  4. 4.
    Sauder DN, Stanulis-Praeger BM, Gilchrest BA: Autocrine growth stimulation of human keratinocytes by epidermal cell-derived thymocyte activating factor: Implications for skin ageing. Arch Dermatol Res 1988; 280:71–76CrossRefPubMedGoogle Scholar
  5. 5.
    Phillips TJ, Manzoor J, Rojas A, et al: The longevity of a bilayered skin substitute after applications to venous ulcers. Arch Dermatol 2002; 138:1079–1081PubMedGoogle Scholar
  6. 6.
    Harding K: Introduction to growth factors. In: Meeting the challenge of managing the diabetic foot: use of growth factor therapy. Proceedings from a symposium preceding the 35th Annual Meeting of the European Association for the Study of Diabetes. Antwerp. 1999; pp 31–40Google Scholar
  7. 7.
    Falanga V, Shen J: Growth factors, signal transduction and cellular responses. In: Falanga V (ed) Cutaneous Wound Healing, 1st edn. London: Martin Dunitz. 2001; pp 81–93Google Scholar
  8. 8.
    Robinson CJ: Growth factors: therapeutic advances in wound healing. Ann Med 1993; 25:535–538PubMedGoogle Scholar
  9. 9.
    Lawrence WT, Diegelmann RF: Growth factors in wound healing. Clin Dermatol 1994; 12:157–169PubMedGoogle Scholar
  10. 10.
    Sporn MB, Roberts AB: A major advance in the use of growth factors to enhance wound healing. J Clin Invest 1993; 92:2565–2566PubMedGoogle Scholar
  11. 11.
    Rohovsky S, D'Amore PA: Growth factors and angio-genesis in wound healing. In: Ziegler TR, Pierce GF, Herndon DN (eds) Growth Factors and Wound Healing: Basic Science and Potential Clinical Applications. Berlin Heidelberg New York: Springer-Verlag. 1997; pp 8–26Google Scholar
  12. 12.
    Greenhalgh DG: The role of growth factors in wound healing. J Trauma 1996; 41:159–167PubMedGoogle Scholar
  13. 13.
    Jaschke E, Zabernigg A, Gattringer C: Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol 1999; 38:380–386CrossRefPubMedGoogle Scholar
  14. 14.
    Declair V: The importance of growth factors in wound healing. Ostomy Wound Manage 1999; 45:64–68, 70–72, 74PubMedGoogle Scholar
  15. 15.
    Gibbs S, Silva-Pinto AN, Murli S, et al: Epidermal growth factor and keratinocyte growth factor differentially regulate epidermal migration, growth, and differentiation. Wound Rep Reg 2000; 8:192–203Google Scholar
  16. 16.
    Mustoe TA, Pierce GF, Thomason A, et al: Accelerated healing of incisional wounds in rats induced by transforming growth factor β. Science 1987; 237:1333–1336PubMedGoogle Scholar
  17. 17.
    Leitzel K, Cano C, Marks JG Jr, et al: Growth factors and wound healing in the hamster. J Dermatol Surg Oncol 1985; 11:617–622PubMedGoogle Scholar
  18. 18.
    McGee GS, Davidson JM, Buckley A, et al: Recombinant basic fibroblast growth factor accelerates wound healing. J Surg Res 1988; 45:145–153CrossRefPubMedGoogle Scholar
  19. 19.
    Hebda PA, Klingbeil CK, Abraham JA, et al: Basic fibroblast growth factor stimulation of epidermal wound healing in pigs. J Invest Dermatol 1990; 95:626–631CrossRefPubMedGoogle Scholar
  20. 20.
    Wu L, Mustoe TA: Effect of ischemia on growth factor enhancement of incisional wound healing. Surgery 1995; 117:570–576PubMedGoogle Scholar
  21. 21.
    Greenhalgh DG, Sprugel KH, Murray MJ, et al: PDGF and FGF stimulate healing in the genetically diabetic mouse. Am J Pathol 1990; 136:1235–1246PubMedGoogle Scholar
  22. 22.
    Brown GL, Nanney LB, Griffen J, et al: Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989; 321:76–79PubMedGoogle Scholar
  23. 23.
    Fu X, Shen Z, Chen Y, et al: Recombinant bovine basic fibroblast growth factor accelerates wound healing in patients with burns, donor sites and chronic dermal ulcers. Chin Med J (Engl) 2000; 113:367–371Google Scholar
  24. 24.
    Cohen MA, Eaglstein WH: Recombinant human platelet-derived growth factor gel speeds healing of acute full-thickness punch biopsy wounds. J Am Acad Dermatol 2001; 45:857–862CrossRefPubMedGoogle Scholar
  25. 25.
    Bello YM, Phillips TJ: Recent advances in wound healing. JAMA 2000; 83:716–718CrossRefGoogle Scholar
  26. 26.
    Konig M, Peschen M, Vanscheidt W: Molecular biology of chronic wounds. In: Hafner J, Ramelet AA, Schmeller W, Brunner UV (eds) Management of Leg Ulcers. Current Problems in Dermatology, vol 27. Basel: Karger. 1999; pp 8–12Google Scholar
  27. 27.
    Castronuovo JJ Jr, Ghobrial I, Giusti AM, et al: Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel. Am J Surg 1998; 176:61S–67SCrossRefPubMedGoogle Scholar
  28. 28.
    Pierce GF, Tarpley JE, Tseng J, et al: Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. J Clin Invest 1995; 96:1336–1350PubMedGoogle Scholar
  29. 29.
    Staiano-Coico L, Higgins PJ, Schwartz SB, et al: Wound fluids: a reflection of the state of healing. Ostomy Wound Manage 2000; 46[1 A Suppl]:85S–93SPubMedGoogle Scholar
  30. 30.
    Trengove NJ, Stacey MC, MacAuley S, et al: Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Rep Reg 1999; 7:442–452CrossRefGoogle Scholar
  31. 31.
    Yager DR, Zhang LY, Liang HX, et al: Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol 1996; 107:743–748CrossRefPubMedGoogle Scholar
  32. 32.
    Kaplan G, Walsh G, Guido LS, et al: Novel responses of human skin to intradermal recombinanat granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitement, keratinocyte growth, and enhanced wound healing. J Exp Med 1992; 175:1717–1728CrossRefPubMedGoogle Scholar
  33. 33.
    Kiritsy CP, Lynch AB, Lynch SE: Role of growth factors in cutaneous wound healing: a review. Crit Rev Oral Biol Med 1993; 4:729–760PubMedGoogle Scholar
  34. 34.
    Robson MC, Mustoe TA, Hunt TK: The future of recombinant growth factors in wound healing. Am J Surg 1998; 176(2A Suppl):80S–82SCrossRefGoogle Scholar
  35. 35.
    Limat A, French LE: Therapy with growth factors. In: Hafner J, Ramelet AA, Schmeller W, Brunner UV (eds) Management of Leg Ulcers. Current Problems in Dermatology, vol 27. Basel: Karger. 1999; pp 49–56Google Scholar
  36. 36.
    Wieman TJ: Clinical efficacy of becaplermin (rhPDGF-BB) gel. Am J Surg 1998; 176[Suppl 2A]:74S–79SCrossRefGoogle Scholar
  37. 37.
    Ross R, Raines EW, Bowen-Pope DF: The biology of platelet-derived growth factor. Cell 1986; 46:155–169CrossRefPubMedGoogle Scholar
  38. 38.
    Lynch SE, Colvin RB, Antoniades HN: Growth factors in wound healing: Single and synergistic effects on partial thickness porcine skin wounds. J Clin Invest 1989; 84:640–646PubMedGoogle Scholar
  39. 39.
    Ross R: Platelet-derived growth factor. Annu Rev Med 1987; 38:71–79CrossRefPubMedGoogle Scholar
  40. 40.
    Yarborough P, Bennet MS, Cannon B, et al: New Product Bulletin — Regranex® (becaplermin) gel. American Pharmaceutical Association. 1998Google Scholar
  41. 41.
    Wieman TJ, Smiell JM, Su Y: Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care 1998; 21:822–827PubMedGoogle Scholar
  42. 42.
    Steed DL: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic ulcer study group. J Vasc Surg 1995; 21:71–78PubMedGoogle Scholar
  43. 43.
    D'Hemecourt PA, Smiell JM, Karim MR: Sodium carboxymethylcellulose aqueous-based gel vs. becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds 1998; 10:69–75Google Scholar
  44. 44.
    Smiell JM, Wieman TJ, Steed DL, et al: Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Rep Reg 1999; 7:335–346CrossRefGoogle Scholar
  45. 45.
    Embil JM, Papp K, Sibbald G, et al: Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. Wound Rep Reg 2000; 8:162–168CrossRefGoogle Scholar
  46. 46.
    Mannari RJ, Payne WG, Ochs DE, et al: Successful treatment of recalcitrant diabetic heel ulcers with topical becaplermin (rh PDGF-BB) gel. Wounds 2002; 14:116–121Google Scholar
  47. 47.
    Rees RS, Robson MC, Smiell JM, et al: Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. Wound Rep Reg 1999; 7:141–147CrossRefGoogle Scholar
  48. 48.
    Kallianinen LK, Hirshberg J, Merchant B, et al: Role of platelet-derived growth factor as an adjunct to surgery in the management of pressure ulcers. Plast Reconstr Surg 2000; 106:1243–1248CrossRefPubMedGoogle Scholar
  49. 49.
    Robson MC, Phillips LG, Thomason A, et al: Plateletderived growth factor BB for the treatment of chronic pressure ulcers. Lancet 1992; 339:23–25CrossRefPubMedGoogle Scholar
  50. 50.
    Wollina U, Liebold K, Konrad H: Treatment of chronic radiation ulcers with recombinant platelet-derived growth factor and a hydrophilic copolymer membrane. J Eur Acad Dermatol Venereol 2001; 15:455–457CrossRefPubMedGoogle Scholar
  51. 51.
    Wieman TJ: Efficacy and safety of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic venous ulcers: a pilot study. Wounds 2003; 15:257–264Google Scholar
  52. 52.
    Steed DL, Donohoe D, Webster MW, et al: Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic ulcer study group. J Am Coll Surg 1996; 183:61–64PubMedGoogle Scholar
  53. 53.
    Robson MC, Phillips LG, Lawrence WT, et al: The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 1992; 216:401–408PubMedGoogle Scholar
  54. 54.
    Robson MC, Phillips TJ, Falanga V, et al: Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Rep Reg 2001; 9:347–352CrossRefGoogle Scholar
  55. 55.
    Robson MC, Smith PD: Topical use of growth factors to enhance healing. In: Falanga V (ed) Cutaneous Wound Healing, 1st edn. London: Martin Dunitz. 2001; pp 379–398Google Scholar
  56. 56.
    Nayeri F, Stromberg T, Larsson M, et al: Hepatocyte growth factor may accelarate healing in chronic leg ulcers: a pilot study. J Dermatolog Treat 2002; 13:81–86CrossRefPubMedGoogle Scholar
  57. 57.
    Groves RW, Schmidt-Lucke JA: Recombinant human GM-CSF in the treatment of poorly healing wounds. Adv Skin Wound Care 2000; 13:107–112PubMedGoogle Scholar
  58. 58.
    Da Costa RM, Aniceto C, Jesus FM, et al: Quick healing of leg ulcers after molgramostim. Lancet 1994; 344:481–482Google Scholar
  59. 59.
    Halabe A, Ingber A, Hodak E, et al: Granulocyte-macrophage colony stimulating factor — a novel therapy in the healing of chronic ulcerative lesions. Med Sci Res 1995; 23:65–66Google Scholar
  60. 60.
    Voskaridou E, Kyrtsonis MC, Loutradi-Anagnostou A: Healing of chronic leg ulcers in the hemoglobinopathies with perilesional injections of granulocyte macrophage colony-stimulating factor. Blood 1999; 93:3568–3569PubMedGoogle Scholar
  61. 61.
    Da Costa RM, Jesus FM, Aniceto C, et al: Doubleblind randomized placebo-controlled trial of the use of granulocyte-macrophage colony-stimulating factor in chronic leg ulcers. Am J Surg 1997; 173:165–168CrossRefPubMedGoogle Scholar
  62. 62.
    Da Costa RM, Jesus FM, Aniceto C, et al: Randomized, double-blind, placebo-controlled, dose-ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers. Wound Repair Regen 1999; 7:17–25CrossRefPubMedGoogle Scholar
  63. 63.
    Jaschke E, Zabernigg A, Gattringer C: Low dose recombinant human granulocyte macrophage colony stimulating factor in the local treatment of chronic wounds. Paper presented at: GM-CSF: New Applications for Wound Healing. Sixth European Conference on Advances in Wound Management. Amsterdam: October 2, 1996Google Scholar
  64. 64.
    Raderer M, Kornek G, Hejna M, et al: Topical granulocyte-macrophage colony-stimulating factor in patients with cancer and impaired wound healing [letter]. J Natl Cancer Inst 1997; 89:263CrossRefPubMedGoogle Scholar
  65. 65.
    Pieters RC, Rojer RA, Saleh AW, et al: Molgramostim to treat SS — sickle cell leg ulcers. Lancet 1995; 345:528CrossRefGoogle Scholar
  66. 66.
    Robson MC, Hill DP, Smith PD, et al: Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response. Ann Surg 2000; 231:600–611CrossRefPubMedGoogle Scholar
  67. 67.
    Starkey RH, Cohen S, Orth DN: Epidermal growth factor: Identification of a new hormone in Human Urine. Science 1975; 189:800–802PubMedGoogle Scholar
  68. 68.
    Tranuzzer RW, Macaulay SP, Mast BA, et al: Epidermal growth factor in wound healing: A model for the molecular pathogenesis of chronic wounds. In: Ziegler TR, Pierce GF, Herndon DN (eds) Growth Factors and Wound Healing: Basic Science and Potential Clinical Applications. Berlin Heidelberg New York: Springer-Verlag. 1997; pp 206–228Google Scholar
  69. 69.
    Carpenter G, Cohen S: Epidermal growth factor. J Biol Chem 1990; 265:7709–7712PubMedGoogle Scholar
  70. 70.
    Laato M, Niinikoski J, Lebel L, et al: Stimulation of wound healing by epidermal growth factor. A dose-dependent effect. Ann Surg 1986; 203:379–381PubMedGoogle Scholar
  71. 71.
    Franklin JD, Lynch JB: Effects of topical applications of epidermal growth factor on wound healing. Experimental study on rabbit ears. Plast Reconstr Surg 1979; 64:766–770PubMedGoogle Scholar
  72. 72.
    Falanga V, Eaglstein WH, Bucalo B, et al: Topical use of human recombinant epidermal growth (h-EGF) in venous ulcers. J Derm Surg Oncol 1992; 18:604–606Google Scholar
  73. 73.
    Gough A, Clapperton M, Rolando N, et al: Randomized placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997; 350:855–859CrossRefPubMedGoogle Scholar
  74. 74.
    De Lalla F, Pellizzer G, Strazzabosco M, et al: Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother 2001; 45:1094–1098PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Personalised recommendations